Heart failure is a clinical syndrome associated with poor quality of life, frequent hospital admissions, and high mortality rates. Since the number of people with heart failure is continuing to rise, it is important to understand the mechanisms that result in disease progression and the medications used to treat it. Clinical trials involving medications that block the neurohormonal systems involved in the disease have shown significant improvements in both hospitalization and mortality rates. Pharmacists who are not experts in heart failure can contribute to the successful management of these patients by understanding key characteristics and drug therapy goals and by communicating regularly with the heart failure patient.
Get full access to this article
View all access options for this article.
References
1.
ArnoldJMLiuPDemersC. Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. Can J Cardiol2006;22(1):23–45.
2.
RemmeWJSwedbergK. Comprehensive guidelines for the diagnosis and treatment of chronic heart failure. Task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Eur J Heart Fail2002;4(1):11–22.
3.
HuntSA. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol2005;46(6):e1–82.
4.
MosterdAHoesAWde BruyneMC. Prevalence of heart failure and left ventricular dysfunction in the general population; The Rotterdam Study. Eur Heart J1999;20(6):447–55.
5.
LevyDKenchaiahSLarsonMG. Long-term trends in the incidence of and survival with heart failure. N Engl J Med2002;347(18):1397–402.
6.
RogerVLWestonSARedfieldMM. Trends in heart failure incidence and survival in a community-based population. JAMA2004;292(3):344–50.
7.
JohansenHStraussBArnoldJMMoeGLiuP. On the rise: the current and projected future burden of congestive heart failure hospitalization in Canada. Can J Cardiol2003;19(4):430–5.
8.
McMurrayJJPetrieMCMurdochDRDavieAP. Clinical epidemiology of heart failure: public and private health burden. Eur Heart J1998;19Suppl P:P9–16.
BhatiaRSTuJVLeeDS. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med2006;355(3):260–9.
11.
CowieMRZaphiriouA. Management of chronic heart failure. BMJ2002;325(7361):422–5.
12.
ArnoldJMHowlettJGDorianP. Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: prevention, management during intercurrent illness or acute decompensation, and use of biomarkers. Can J Cardiol2007;23(1):21–45.
13.
CowieMRWoodDACoatsAJ. Incidence and aetiology of heart failure; a population-based study. Eur Heart J1999;20(6):421–8.
14.
MohanSBParkerMWehbiMDouglassP. Idiopathic dilated cardiomyopathy: a common but mystifying cause of heart failure. Cleve Clin J Med2002;69(6):481–7.
15.
McMurrayJJStewartS. Epidemiology, aetiology, and prognosis of heart failure. Heart2000;83(5):596–602.
16.
JahnsRBoivinVLohseMJ. Beta(1)-adrenergic receptor function, autoimmunity, and pathogenesis of dilated cardiomyopathy. Trends Cardiovasc Med2006;16(1):20–4.
17.
BleskeBE. Evolution and pathophysiology of chronic systolic heart failure. Pharmacotherapy2000;20(11 Pt 2):349S–58S.
18.
AdamsKFJr. Pathophysiologic role of the renin-angiotensin-aldosterone and sympathetic nervous systems in heart failure. Am J Health Syst Pharm2004;61Suppl 2:S4–13.
19.
JessupMBrozenaS. Heart failure. N Engl J Med2003;348(20):2007–18.
20.
MungerMACheangKI. Beta-blocker therapy: a standard of care for heart failure. Pharmacotherapy2000;20(11 Pt 2):359S–67S.
21.
BristowMR. Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking agents. Am J Cardiol1993;71(9):12C–22C.
22.
SabbahHN. Biologic rationale for the use of beta-blockers in the treatment of heart failure. Heart Fail Rev2004;9(2):91–7.
23.
BristowMR. Beta-adrenergic receptor blockade in chronic heart failure. Circulation2000;101(5):558–69.
24.
AnandISFloreaVGFisherL. Surrogate end points in heart failure. J Am Coll Cardiol2002;39(9):1414–21.
25.
The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med1997;336(8):525–33.
26.
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med1991;325(5):293–302.
27.
Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet1993;342(8875):821–8.
28.
PackerMPoole-WilsonPAArmstrongPW. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation1999;100(23):2312–8.
29.
Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med1987;316(23):1429–35.
30.
KoberLTorp-PedersenCCarlsenJE. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med1995;333(25):1670–6.
31.
PfefferMABraunwaldEMoyeLA. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med1992;327(10):669–77.
32.
PattersonJHRodgersJE. Expanding role of beta-blockade in the management of chronic heart failure. Pharmacotherapy2003;23(4):451–9.
33.
Poole-WilsonPASwedbergKClelandJG. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet2003;362(9377):7–13.
34.
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet1999;353(9169):2001–7.
35.
DargieHJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet2001;357(9266):1385–90.
36.
PackerMCoatsAJFowlerMB. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med2001;344(22):1651–8.
37.
PackerMBristowMRCohnJN. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med1996;334(21):1349–55.
38.
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet1999;353(9146):9–13.
39.
ChaveyWEIIBlaumCSBleskeBE. Guideline for the management of heart failure caused by systolic dysfunction: part II. Treatment. Am Fam Physician2001;64(6):1045–54.
40.
A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med2001;344(22): 1659–67.
41.
PittBPoole-WilsonPASegalR. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial — the Losartan Heart Failure Survival Study ELITE II. Lancet2000;355(9215):1582–7.
42.
CohnJNTognoniG. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med2001;345(23):1667–75.
43.
PfefferMAMcMurrayJJVelazquezEJ. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med2003;349(20):1893–906.
44.
GrangerCBMcMurrayJJYusufS. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet2003;362(9386):772–6.
45.
McMurrayJJOstergrenJSwedbergK. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet2003;362(9386):767–71.
46.
PfefferMASwedbergKGrangerCB. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet2003;362(9386):759–66.
47.
YusufSPfefferMASwedbergK. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet2003;362(9386):777–81.
48.
McKelvieRSYusufSPericakD. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation1999;100(10):1056–64.
49.
DicksteinKKjekshusJ. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet2002;360(9335):752–60.
50.
PittBZannadFRemmeWJ. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med1999;341(10):709–17.
51.
JuurlinkDNMamdaniMMLeeDS. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med2004;351(6):543–51.
52.
TaylorALZiescheSYancyC. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med2004;351(20):2049–57.
53.
BleuminkGSKnetschAMSturkenboomMC. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur Heart J2004;25(18):1614–9.
54.
CeiaFFonsecaCMotaT. Prevalence of chronic heart failure in Southwestern Europe: the EPICA study. Eur J Heart Fail2002;4(4):531–9.
